What is the Safety Profile of Voclosporin and How Should it be Monitored?

Learn about the safety profile and monitoring requirements of voclosporin for lupus nephritis with Jessica Farrell, PharmD, an experienced rheumatology pharmacist and faculty member at the Albany College of Pharmacy and Health Sciences. In this video, Jessica Farrell explains what makes voclosporin—a second-generation calcineurin inhibitor—unique, including its increased potency, improved pharmacokinetic profile, and reduced need for therapeutic drug level monitoring compared to cyclosporine.

Jessica Farrell discusses key considerations before initiating voclosporin in patients with lupus nephritis, such as baseline eGFR, blood pressure, and ongoing laboratory assessments. Discover the recommended monitoring schedule for renal function, urine protein, blood pressure, and potassium levels, as well as important safety warnings including the risk of infections, malignancy, neurotoxicity, and QT prolongation.

Find out how voclosporin may have a more favorable impact on lipids and glucose compared to other calcineurin inhibitors, and why proper patient selection and routine monitoring are essential for optimal outcomes in lupus nephritis care.

For more expert resources on voclosporin and lupus nephritis, visit the RhAPP website or download the RhAPP ACE app. Don’t forget to join us at the annual RhAPP conference in September for the latest updates in rheumatology care.